All In Biotech

Drug Trial Radar · NCT03790085

Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals

Last checked: Nov 19, 2026Latest source record: Dec 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

2,700

Planned (sponsor's estimate)

Start

Sep 1, 2018

Primary completion

Jun 30, 2020

Study completion Dec 31, 2020

Sponsor

Lead sponsor
Tianjin Medical University General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai Mental Health Center; Nanjing Medical University; Tianjin Anding Hospital; Harbin First Specialist Hospital; First Affiliated Hospital of Chongqing Medical University; Anhui Mental Health Center; Wuhan Psychiatric Hospital; Wenzhou Seventh People's Hospital; First Affiliated Hospital of Harbin Medical University
First posted
Dec 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures. Based on the validated bio-markers, the present study further tries to build several prediction models for early differential diagnosis of schizophrenia from healthy controls and other mental diseases (such as the major depression and anxiety disorders), biological sub-typing and diagnosis of the schizophrenia sub-types, and early prediction of the medication effects.

Conditions

  • Schizophrenia
  • Major Depressive Disorder
  • Anxiety Disorders

Interventions

  • RisperidoneDrug

    Risperidone tablet

  • OlanzapineDrug

    Olanzapine tablet

  • AripiprazoleDrug

    Aripiprazole tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive and Negative Syndrome Scale (PANSS)Time frame: 30-45 minutes
  2. Clinical Global Impression(CGI)Time frame: 10-15 minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University General Hospital

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.